Previous close | 38.31 |
Open | 39.25 |
Bid | 37.43 x 600 |
Ask | 37.53 x 300 |
Day's range | 36.92 - 39.25 |
52-week range | 15.44 - 40.21 |
Volume | |
Avg. volume | 1,486,380 |
Market cap | 6.179B |
Beta (5Y monthly) | 1.46 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript May 8, 2024 Revolution Medicines, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to Revolution Medicine’s First Quarter 2024 Earnings Conference […]
Explore key insights from Revolution Medicines' Q1 2024 earnings, focusing on R&D progress and financial metrics.
On May 3, 2024, Jack Anders, the Chief Financial Officer of Revolution Medicines Inc (NASDAQ:RVMD), sold 10,000 shares of the company.